Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series
This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and qua...
Saved in:
| Published in | mSphere Vol. 5; no. 6 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society for Microbiology
11.11.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms.
Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14
+
CD16
+
monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease.
IMPORTANCE
This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms. |
|---|---|
| AbstractList | This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms.
Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14
+
CD16
+
monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease.
IMPORTANCE
This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms. ABSTRACT Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14+ CD16+ monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease. IMPORTANCE This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms. Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14+ CD16+ monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease.IMPORTANCE This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms.Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14+ CD16+ monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease.IMPORTANCE This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms. Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse transcriptase PCR (RT-PCR) until days 7 and 19 after symptom onset, respectively. Robust innate responses characterized by increases in activated CD14 CD16 monocytes and cytokine responses were observed as early as 2 days after symptom onset. Cellular and humoral severe acute respiratory syndrome (SARS)-CoV-2-specific adaptive responses were detectable in all patients. Infectious virus shedding was limited to the first week after symptom onset. A strong innate response, characterized by mobilization of activated monocytes during the first days of infection and SARS-CoV-2-specific antibodies, was detectable even in patients with mild disease. This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other studies assess these separately. We describe the detailed viral and immune profiles of the first five patients infected by SARS-CoV-2 and quarantined in Geneva, Switzerland. Viral loads peaked at the very beginning of the disease, and infectious virus was shed only during the early acute phase of disease. No infectious virus could be isolated by culture 7 days after onset of symptoms, while viral RNA was still detectable for a prolonged period. Importantly, we saw that all patients, even those with mild symptoms, mount an innate response sufficient for viral control (characterized by early activated cytokines and monocyte responses) and develop specific immunity as well as cellular and humoral SARS-CoV-2-specific adaptive responses, which already begin to decline a few months after the resolution of symptoms. |
| Author | Laubscher, Florian Vu, Diem-Lan Kaiser, Laurent Cordey, Samuel Didierlaurent, Arnaud M. Lemeille, Sylvain Schibler, Manuel Calame, Adrien Vetter, Pauline Eberhardt, Christiane S. Martinez Murillo, Paola Andrea Torriani, Giulia Meyer, Benjamin Jacquerioz, Frederique Siegrist, Claire-Anne Blanchard-Rohner, Géraldine Eckerle, Isabella Pigny, Fiona |
| Author_xml | – sequence: 1 givenname: Pauline orcidid: 0000-0002-9902-5069 surname: Vetter fullname: Vetter, Pauline organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 2 givenname: Christiane S. surname: Eberhardt fullname: Eberhardt, Christiane S. organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland, Emory Vaccine Center, Emory University, Atlanta, Georgia, USA – sequence: 3 givenname: Benjamin surname: Meyer fullname: Meyer, Benjamin organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland – sequence: 4 givenname: Paola Andrea surname: Martinez Murillo fullname: Martinez Murillo, Paola Andrea organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland – sequence: 5 givenname: Giulia surname: Torriani fullname: Torriani, Giulia organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 6 givenname: Fiona surname: Pigny fullname: Pigny, Fiona organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland – sequence: 7 givenname: Sylvain surname: Lemeille fullname: Lemeille, Sylvain organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland – sequence: 8 givenname: Samuel surname: Cordey fullname: Cordey, Samuel organization: Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 9 givenname: Florian surname: Laubscher fullname: Laubscher, Florian organization: Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 10 givenname: Diem-Lan surname: Vu fullname: Vu, Diem-Lan organization: Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 11 givenname: Adrien surname: Calame fullname: Calame, Adrien organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland – sequence: 12 givenname: Manuel surname: Schibler fullname: Schibler, Manuel organization: Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 13 givenname: Frederique surname: Jacquerioz fullname: Jacquerioz, Frederique organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 14 givenname: Géraldine surname: Blanchard-Rohner fullname: Blanchard-Rohner, Géraldine organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland – sequence: 15 givenname: Claire-Anne surname: Siegrist fullname: Siegrist, Claire-Anne organization: Center for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Division of General Pediatrics, Geneva University Hospitals, Geneva, Switzerland – sequence: 16 givenname: Laurent surname: Kaiser fullname: Kaiser, Laurent organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland – sequence: 17 givenname: Arnaud M. surname: Didierlaurent fullname: Didierlaurent, Arnaud M. organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Emory Vaccine Center, Emory University, Atlanta, Georgia, USA – sequence: 18 givenname: Isabella surname: Eckerle fullname: Eckerle, Isabella organization: Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland, Faculty of Medicine, University of Geneva, Geneva, Switzerland, Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33177214$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Uk1v1DAQjVARLaV3TshHLin-ip1wQFptoY2oVIlCr9bYnm1dJU6Is5X67_F-ULVIXOyR57038zzztjiIQ8SieM_oKWO8_tRfj3c44SmlNdclp6-KIy50U1ZU8oNn8WFxktI9pZQprpRWb4pDIZjWnMmjwp5B6B7JTZigI99DxDm4RCB60sYIM27DhYdxDg9I2r5fRyQ_MI1DTEgWKWFKPcaZhEiWVzftWcmazwTIEnL6GqeA6V3xegVdwpP9fVz8-vb15_KivLw6b5eLy9JVvJ5LUXGpRdXYBnwD1noqNViBVmQPVjsQqgZUK94AQ8-5Bue4lyofK980jTgu2p2uH-DejFPoYXo0AwSzfRimWwNTttehYVm5slBRQCk5dba2SK2y1kkvPYis9WWnNa5tj95lh_mDXoi-zMRwZ26HB6NVpat608zHvcA0_F5jmk0fksOug4jDOhkuVZ6bVJxn6IfntZ6K_B1SBtAdwE1DShOuniCMms0qmP0qmO0qGE4zRf1DcWGGOQybbkP3f-IfiOa6tQ |
| CitedBy_id | crossref_primary_10_32607_actanaturae_26623 crossref_primary_10_1038_s41541_023_00717_8 crossref_primary_10_3390_ijms252111632 crossref_primary_10_1038_s41579_022_00822_w crossref_primary_10_1038_s43856_022_00195_4 crossref_primary_10_3390_su14073896 crossref_primary_10_1016_j_jiph_2021_05_003 crossref_primary_10_7554_eLife_65774 crossref_primary_10_1089_vim_2020_0177 crossref_primary_10_1002_emp2_12605 crossref_primary_10_3389_fmed_2021_648660 crossref_primary_10_1371_journal_pone_0253321 crossref_primary_10_2174_0122113525284502240217161226 crossref_primary_10_52547_hrjbaq_7_2_87 crossref_primary_10_1038_s41591_022_01816_0 crossref_primary_10_7554_eLife_70458 crossref_primary_10_1007_s10875_021_01134_z crossref_primary_10_1186_s12916_021_02220_0 crossref_primary_10_1016_j_virusres_2023_199255 crossref_primary_10_52547_hrjbaq_6_3_219 crossref_primary_10_3389_fimmu_2022_841009 crossref_primary_10_1093_cid_ciab396 crossref_primary_10_1016_j_cmi_2021_02_010 crossref_primary_10_23749_mdl_v113i2_12724 crossref_primary_10_3390_math12172681 crossref_primary_10_3389_fmicb_2022_912138 crossref_primary_10_3390_pharmaceutics13101612 crossref_primary_10_1016_j_diagmicrobio_2021_115612 crossref_primary_10_1021_acsami_1c16930 crossref_primary_10_1038_s41564_023_01356_4 crossref_primary_10_1038_s41467_022_30833_3 crossref_primary_10_3390_microorganisms12030428 crossref_primary_10_34067_KID_0004372021 crossref_primary_10_26693_jmbs06_03_053 crossref_primary_10_1002_jcla_25137 crossref_primary_10_3390_biomedicines10040772 crossref_primary_10_3390_ijms25158155 crossref_primary_10_1016_j_intimp_2022_108697 crossref_primary_10_1371_journal_pone_0248921 |
| Cites_doi | 10.1016/S0140-6736(20)30183-5 10.1038/s41577-020-0331-4 10.1038/s41591-020-0869-5 10.1038/s41591-020-0901-9 10.2807/1560-7917.ES.2020.25.3.2000045 10.1016/j.cmi.2020.06.024 10.1016/j.vaccine.2020.05.064 10.1016/j.cell.2020.05.015 10.1126/sciimmunol.abd2071 10.1093/infdis/jiaa392 10.1016/j.chom.2014.06.001 10.1128/JCM.01389-14 10.1136/bmj.m1470 10.1172/JCI137244 10.1111/j.1365-2036.2011.04807.x 10.1056/NEJMoa2001282 10.1128/JVI.01744-18 10.1016/j.jcv.2020.104370 10.1371/journal.pone.0017484 10.1101/2020.03.24.20042655 10.1126/science.abc6027 10.1093/cid/ciaa424 10.1038/s41591-020-0819-2 10.1371/journal.pone.0025858 10.3389/fimmu.2017.00272 10.1136/bmj.m1328 10.1038/s41586-020-2196-x 10.1002/jmv.25948 10.1099/vir.0.80955-0 10.1093/nsr/nwaa041 10.1038/s41421-020-0168-9 10.1016/S1473-3099(20)30232-2 10.1038/s41577-020-0321-6 10.1111/j.1365-2567.2009.03224.x |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Vetter et al. Copyright © 2020 Vetter et al. 2020 Vetter et al. |
| Copyright_xml | – notice: Copyright © 2020 Vetter et al. – notice: Copyright © 2020 Vetter et al. 2020 Vetter et al. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1128/mSphere.00827-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Viral and Immune Profiling in COVID-19 |
| EISSN | 2379-5042 |
| ExternalDocumentID | oai_doaj_org_article_17ab5ba50ae4420cb8be0b6bbc4d4da3 PMC7657589 33177214 10_1128_mSphere_00827_20 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | 0R~ 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAGFI AAUOK AAYXX ABUWG ADBBV AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CITATION DIK EBS FRP FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE KQ8 LK8 M48 M7P M~E O9- OK1 PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC R9- RHI RPM RSF UKHRP CGR CUY CVF ECM EIF NPM PQGLB 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c528t-35247359b9ad9abbd047ab3eb3042b7ca368ae6f29a1ed227acc2d46c2dfd9993 |
| IEDL.DBID | M48 |
| ISSN | 2379-5042 |
| IngestDate | Wed Aug 27 01:31:04 EDT 2025 Thu Aug 21 14:02:18 EDT 2025 Fri Jul 11 00:50:16 EDT 2025 Mon Jul 21 05:52:10 EDT 2025 Thu Apr 24 22:51:04 EDT 2025 Tue Jul 01 02:17:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | COVID-19 SARS-CoV-2 cytokines antibody response viral load immunity |
| Language | English |
| License | Copyright © 2020 Vetter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c528t-35247359b9ad9abbd047ab3eb3042b7ca368ae6f29a1ed227acc2d46c2dfd9993 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Pauline Vetter, Christiane S. Eberhardt, Benjamin Meyer, and Paola Andrea Martinez Murillo contributed equally. Author order reflects their clinical (Pauline Vetter), cell-mediated (Christiane S. Eberhardt), serological (Benjamin Meyer), and cytokine (Paola Andrea Martinez Murillo) immunological work, but without any differences in their positions reflecting their contributions. Arnaud M. Didierlaurent and Isabella Eckerle are co-senior authors. Citation Vetter P, Eberhardt CS, Meyer B, Martinez Murillo PA, Torriani G, Pigny F, Lemeille S, Cordey S, Laubscher F, Vu D-L, Calame A, Schibler M, Jacquerioz F, Blanchard-Rohner G, Siegrist C-A, Kaiser L, Didierlaurent AM, Eckerle I. 2020. Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: a case series. mSphere 5:e00827-20. https://doi.org/10.1128/mSphere.00827-20. |
| ORCID | 0000-0002-9902-5069 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1128/mSphere.00827-20 |
| PMID | 33177214 |
| PQID | 2460084622 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_17ab5ba50ae4420cb8be0b6bbc4d4da3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7657589 proquest_miscellaneous_2460084622 pubmed_primary_33177214 crossref_primary_10_1128_mSphere_00827_20 crossref_citationtrail_10_1128_mSphere_00827_20 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20201111 |
| PublicationDateYYYYMMDD | 2020-11-11 |
| PublicationDate_xml | – month: 11 year: 2020 text: 20201111 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | mSphere |
| PublicationTitleAlternate | mSphere |
| PublicationYear | 2020 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 L'Huillier A (e_1_3_2_34_2) 2020 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
| References_xml | – ident: e_1_3_2_3_2 doi: 10.1016/S0140-6736(20)30183-5 – ident: e_1_3_2_16_2 doi: 10.1038/s41577-020-0331-4 – ident: e_1_3_2_17_2 doi: 10.1038/s41591-020-0869-5 – ident: e_1_3_2_22_2 doi: 10.1038/s41591-020-0901-9 – ident: e_1_3_2_33_2 doi: 10.2807/1560-7917.ES.2020.25.3.2000045 – ident: e_1_3_2_36_2 doi: 10.1016/j.cmi.2020.06.024 – ident: e_1_3_2_30_2 doi: 10.1016/j.vaccine.2020.05.064 – ident: e_1_3_2_11_2 doi: 10.1016/j.cell.2020.05.015 – ident: e_1_3_2_13_2 doi: 10.1126/sciimmunol.abd2071 – ident: e_1_3_2_28_2 doi: 10.1093/infdis/jiaa392 – ident: e_1_3_2_25_2 doi: 10.1016/j.chom.2014.06.001 – ident: e_1_3_2_31_2 – ident: e_1_3_2_35_2 doi: 10.1128/JCM.01389-14 – ident: e_1_3_2_4_2 doi: 10.1136/bmj.m1470 – ident: e_1_3_2_6_2 doi: 10.1172/JCI137244 – ident: e_1_3_2_27_2 doi: 10.1111/j.1365-2036.2011.04807.x – ident: e_1_3_2_14_2 doi: 10.1056/NEJMoa2001282 – start-page: 202004272007677 year: 2020 ident: e_1_3_2_34_2 article-title: Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents publication-title: medRxiv – ident: e_1_3_2_38_2 doi: 10.1128/JVI.01744-18 – ident: e_1_3_2_7_2 doi: 10.1016/j.jcv.2020.104370 – ident: e_1_3_2_9_2 doi: 10.1371/journal.pone.0017484 – ident: e_1_3_2_21_2 doi: 10.1101/2020.03.24.20042655 – ident: e_1_3_2_10_2 doi: 10.1126/science.abc6027 – ident: e_1_3_2_19_2 doi: 10.1093/cid/ciaa424 – ident: e_1_3_2_12_2 doi: 10.1038/s41591-020-0819-2 – ident: e_1_3_2_37_2 doi: 10.1371/journal.pone.0025858 – ident: e_1_3_2_26_2 doi: 10.3389/fimmu.2017.00272 – ident: e_1_3_2_8_2 doi: 10.1136/bmj.m1328 – ident: e_1_3_2_18_2 doi: 10.1038/s41586-020-2196-x – ident: e_1_3_2_15_2 doi: 10.1002/jmv.25948 – ident: e_1_3_2_39_2 doi: 10.1099/vir.0.80955-0 – ident: e_1_3_2_23_2 doi: 10.1093/nsr/nwaa041 – ident: e_1_3_2_20_2 doi: 10.1038/s41421-020-0168-9 – ident: e_1_3_2_5_2 doi: 10.1016/S1473-3099(20)30232-2 – ident: e_1_3_2_32_2 – ident: e_1_3_2_29_2 doi: 10.1038/s41577-020-0321-6 – ident: e_1_3_2_24_2 doi: 10.1111/j.1365-2567.2009.03224.x – ident: e_1_3_2_2_2 |
| SSID | ssj0001626676 |
| Score | 2.3579283 |
| Snippet | This work is particularly important because it simultaneously assessed the virology, immunology, and clinical presentation of the same subjects, whereas other... Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We... ABSTRACT Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19).... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| SubjectTerms | Adaptive Immunity Adult Aged Antibodies, Viral - metabolism antibody response Betacoronavirus - immunology Betacoronavirus - isolation & purification Biomarkers - metabolism Clinical Laboratory Techniques Clinical Science and Epidemiology Coronavirus Infections - diagnosis Coronavirus Infections - immunology Coronavirus Infections - virology COVID-19 COVID-19 Testing cytokines Cytokines - metabolism Humans immunity Immunity, Innate Kinetics Middle Aged Pandemics Pneumonia, Viral - diagnosis Pneumonia, Viral - immunology Pneumonia, Viral - virology SARS-CoV-2 Severity of Illness Index Viral Load Virus Shedding |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQpUpcEFAeKaUyEhcO1mYdx056W7ZUXRAgAa16s8aPiJWKW7XbQ_89M04a7aIKLlyiKHESa2ac-cYef8PY26ryARBoiA7qVqgYKtFqo0RZ1SbSvpDaUaD4-Ys-PlEfz-qztVJflBPW0wP3gptMDbjaQV1CVEqW3jUulk4751VQATLPJ_q8tWAqz64gTtdmXJeUzeTXd9qmH4nOVBpB5b3X_FCm678PY_6ZKrnme44es0cDaOSzvrNP2IOYnrLtvozk7Q5zh7A8v-WnS3yUf0LYSNTLHFLgi5QQS-bTWYBL-rXxBe0Iifxbnxwb-Wzk5uTLxOdfTxeHYtoecOBz9HCcps_i9TN2cvThx_xYDLUThK9lsxKIq6iocOtaCC04F0qFgqwwdMZR6oyHSjcQdSdbmMYgpQHvZVAaD11A0Fg9Z1vpIsWXjINT3pfKaUk1OWQE1eBboezqLgKqpWCTO0laPxCLU32Lc5sDDNnYQfY2y97KsmDvxicue1KNv7R9T8oZ2xEddr6ARmIHI7H_MpKCvblTrcXhQ2sikOLFzbWVSlNJAS1lwV70qh4_VSG2wgBZFcxsGMFGXzbvpOXPTNFtaD2raXf_R-dfsYeSgnzKPZzusa3V1U18jUho5faz0f8GMnEKQQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33177214 https://www.proquest.com/docview/2460084622 https://pubmed.ncbi.nlm.nih.gov/PMC7657589 https://doaj.org/article/17ab5ba50ae4420cb8be0b6bbc4d4da3 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfYJiReEN9kQGUkXngISx3HTpAQyrpNK9M2NOjUt-j8EajUpaPtJPrfc5dkgaKKJ16SKLGTy10u9zvbd8fYmzi2DhBohCUkWSi9i8NMaRlGcaI9xYUkhhzF0zN1PJKfxsn4d3h0y8DFRteO6kmN5tN3P3-sPqLCf2gCYNK9qy8Uge8pU6nQKPYttoN2SVM9g9MW7NcjLojdle7mKjd0XLNNdQr_Tbjz7-WTf9ijowfsfgsked5I_iG746tH7G5TWnL1mJkDmExX_HKCXfkJQklKx8yhcnxYVYgv68PcwTX97viQokQ8v2gWzHqed_k6-aTig_PL4UHYz95z4AO0epyG1PziCRsdHX4dHIdtPYXQJiJdhoi1qNBwZjJwGRjjIqnBxOhOo-YabSFWKXhVigz63gmhwVrhpMJN6RBIxk_ZdjWr_HPGwUhrI2mUoDodwoNM8a4QlUnpIQIfsL1bTha2TTZONS-mRe10iLRoeV_UvC9EFLC3XY_rJtHGP9ruk3C6dpQiuz4xm38rWo0r-vhuiYEEqUEKI2tS4yOjjLHSSQdxwF7firZAlaJ5Eqj87GZRCKmozIASImDPGlF3j4oRb6HTLAOm1z6CNVrWr1ST73Xabk1zXGm2-z-If8HuCXL8aT1i_yXbXs5v_CtER0vTY1t6rHtsJ89H5ye43z88-3zRq8caerVC_AK_Dxbk |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daily+Viral+Kinetics+and+Innate+and+Adaptive+Immune+Response+Assessment+in+COVID-19%3A+a+Case+Series&rft.jtitle=mSphere&rft.au=Pauline+Vetter&rft.au=Christiane+S.+Eberhardt&rft.au=Benjamin+Meyer&rft.au=Paola+Andrea+Martinez+Murillo&rft.date=2020-11-11&rft.pub=American+Society+for+Microbiology&rft.eissn=2379-5042&rft.volume=5&rft.issue=6&rft_id=info:doi/10.1128%2FmSphere.00827-20&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_17ab5ba50ae4420cb8be0b6bbc4d4da3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2379-5042&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2379-5042&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2379-5042&client=summon |